An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

Background: Immunocompromised individuals have a limited humoral immune response to SARS-CoV-2 vaccination and are at higher risk of severe COVID-19. Sotrovimab is a monoclonal antibody (mAb) targeting a conserved SARS-CoV-2 spike protein epitope. Methods: This phase II open-label study evaluated th...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabel H. Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, Fabiola A. Reyes Curcio, Andres E. Franceschi, Chloe Lahoud, Dimitrios G. Moshovitis, Katherine Beluch, Manu Balusu, C. Elizabeth Keleher, Keri M. Sullivan, Michael Dougan, Qianwen Wang, Jennifer H. Han, Ahmed Nader, Alicia Aylott, Wei Wang, Brian T. Chan, Sarah P. Hammond, Jennifer Manne-Goehler, Sophia Koo
Format: Article
Language:English
Published: Elsevier 2025-10-01
Series:New Microbes and New Infections
Subjects:
Immunocompromised host
Covid-19
Pre-exposure prophylaxis
Monoclonal antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2052297525000599
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2052297525000599

Similar Items